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The Brighton declaration arose out of a one day workshop
held in Brighton in September 2013 as part of the Society
for Social Medicine annual conference. The workshop
convened UK based non-communicable disease modellers
to discuss the challenges and opportunities for non-com-
municable disease modelling in the UK. The declaration
describes the value and importance of non-communicable
disease modelling, both for research and for informing
health policy. The declaration also describes challenges
and issues for non-communicable disease modelling. The
declaration has been endorsed by many non-communicable
disease modellers in the UK.
Background
Over 60 % of global deaths are attributable to non-com-
municable diseases (NCDs) [1]. With most developing
countries experiencing a shift in disease burden away from
communicable disease to NCDs, this contribution is
expected to grow. To respond effectively, it will be crucial
to understand these epidemics better: both how the burden
of disease is anticipated to change over time based on
current trends (e.g. demographic change, changes in risk
factor prevalence, or changes in diseases incidence), and
the effects that different interventions might have. This is
important for planning health services and for developing
an evidence base to inform public health policies aimed at
reducing the burden of disease. While modelling is often
not well understood and is frequently criticised, we argue
that modelling NCDs has an important role to play in
informing how society responds their increasing burden on
population health.
What is non-communicable disease modelling?
Models simplify reality—a good model represents those
parts of reality that matter and leaves out those parts that do
not. Modelling is the development and use of these models
to understand how different inputs (e.g. behaviours) affect
different outcomes (e.g. disease). NCD modelling is a
method for estimating the extent to which changes in one
or more risk factor (e.g. smoking and diet) affects disease
and health. It has two broad uses, health impact modelling
(understanding the effect of prevention, screening or
treatment interventions on health) [2] and forecasting
(estimating disease trends based on demographic change or
predicted changes in risk factors, including making
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allowance for competing risk). Such modelling is some-
times extended to consider the costs to society or health
systems that arise from disease, and the potential savings
that may accrue from interventions. NCD models use a
wide range of research methods and can answer a range of
questions [3–6]. NCD modelling in the UK is performed by
(and used by) a variety of institutions, academic research
units, non-government organisations, as well as public
bodies. Although such modelling is not new, increased
availability of datasets, improved computational power and
use of new methods is opening up new possibilities [7].
The need and use for non-communicable disease
modelling
Modelling is already widely used to inform decision
making in both the public and private sector. Within public
health it has long been recognised that the greatest influ-
ences on population health lie outside the health sector [8].
NCD modelling has, for example, been influential in the
debate on minimum unit pricing [9] and is being used to
integrate health into transport planning [10, 11]. NCD
modelling may also be used to inform decisions on prior-
ities for investment, for example modelling cost-effec-
tiveness of different interventions for primary prevention
of cardiovascular disease [12] or different approaches to
screening [13, 14], as well as predict future trends in dis-
ease burden [13], which are important in planning health
service provision.
Modelling enables us to estimate the long term and
population-wide health effects of interventions. These
effects are rarely observed in a single research study
because of a variety of other influences on the observed
outcome over time, and true randomised experiments are
often not practical. While modelling studies can be cheaper
and quicker than real world studies, they should be seen as
a complement to such studies, and may help us get the best
value out of such studies. It is often most appropriate to
model when we already have a good understanding of the
system being modelled, both its structures and its param-
eters. Often in this way modelling studies are being used to
integrate evidence from different studies and different
domains. Modelling can also inform empirical studies, for
example to identify assumptions or key parts of evidence
that may have a significant impact on model outcome
(direct empirical study of these assumptions may give
greater confidence in the model and its predictions).
Modelling may also be used to estimate likely effect sizes
to inform the size of evaluative studies.
For example our understanding of the effectiveness and
cost-effectiveness of the current UK Breast Cancer
Screening programme is informed by modelling [14, 15].
While estimates of the effectiveness of screening could be
derived from past trials, these occurred many years ago,
when incidence was lower, diagnostic technology different,
and treatment options fewer. Our knowledge of the system
and the parameters within the system is relatively good. It
also serves as an example of modelling being comple-
mentary to, and used alongside, ‘‘empirical’’ evidence.
While such modelling does not preclude the need for a
trial, it can give a more rapid indication of where the costs
and benefits lie. Indeed, estimates could be updated on a
periodic basis as disease trends change and technology
evolves. Further, modelling could demonstrate that the
existing evidence is sufficient, such that further empirical
studies may not be necessary.
Criticisms of non-communicable disease modelling
Modelling work is often criticised. This may relate to
criticisms of the underlying assumptions within the model:
either the particular values (parameters) used or the mod-
el’s structure (the assumed underlying relationships or
causal model). Some of these assumptions may be implicit
within the model, and there is a risk that they may not be
readily identified as assumptions by those building (and
using) the model. This can be particularly problematic
when there is either no or limited evidence to support these
assumptions. Sometimes the criticism relates to the very
idea of modelling, that modelling is by definition, uncer-
tain, resulting in the view that the model will lead to
unrealistic estimates. These fears may be compounded if a
clear description of the model, ideally one that is accessible
to a wide audience, is not given. Developing such a clear
description is not always straightforward and requires the
ability to articulate many of the key assumptions sur-
rounding model structure (including implicit assumptions)
to non-specialist audiences.
While criticisms of the underlying assumptions may
sometimes be justified, sensitivity analyses can be used to
identify which explicit assumptions are critical to the
model (in terms of having a significant impact on the model
outcome), and uncertainty analyses can quantify uncer-
tainty surrounding the model’s parameters and structure;
both are important for calibration and validation of the
model. Within the bounds of expected values some
underlying assumptions and parameters may have little
effect on the model results even though the uncertainty
surrounding those particular parameters may be high [16].
While there may be times that uncertainty is so great that
the results cannot be used in decision making, we believe a
best estimate can often be better than no estimate. Failure
to model health outcomes may mean failure to consider
health, alongside many of the other outcomes that may be
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modelled (and considered) for prospective policies, for
example employment, revenues, and carbon emissions, and
ill health is expensive especially in the future. It might also
mean that decision making is informed by decision makers’
best guesses as to what the costs and benefits are—effec-
tively ‘‘implicit modelling’’ which is unstructured, non-
transparent, and not reproducible.
Challenges for modelling
A number of challenges have been identified:
• perception that conclusions are largely assumption
based and that underlying (and sometimes implicit)
assumptions are being hidden or chosen in such a way
to support a particular outcome;
• conceptualising and communicating issues of uncer-
tainty, particularly to policy makers;
• communicating to both technical and non-technical
audiences how the modelling was undertaken and the
nature of the underlying assumptions;
• presenting study results in an accessible way to reach
an audience that may not be familiar with technical
details and issues of modelling;
• journals having difficulty identifying appropriate han-
dling editors and referees with correct technical expertise;
• journal editors lacking familiarity with modelling
approaches and being unsure how to appraise quality;
• findings being reported too strongly, particularly where
unacknowledged or implicit assumptions may under-
mine the validity of the model.
Need for standardised reporting guidelines
We recognise that some of these issues might be resolved
by improved and standardised reporting of modelling
studies. Transparent acknowledgements of assumptions
and limitations (including using non-technical language)
enables a more thorough and robust peer-review and allows
readers to assess the model’s quality [17–19]. Unfortu-
nately, to our knowledge there is no reporting guideline
(e.g. Enhancing the QUAlity and Transparency Of health
Research (EQUATOR) network guidelines: www.equator-
network.org) for NCD modelling nor are we aware of any
equivalent reporting standards.
Health economics, which often draws on modelling, has
reporting guidelines and some of these cover modelling
[e.g. Consolidated Health Economic Evaluation Reporting
Standards (CHEERS)] [20]. There are also separate stan-
dards for the reporting of health economic modelling [21].
While these guidelines may partially address the needs of
NCD modelling, we do not think they are sufficient.
Besides having a large focus on economic outcomes, the
economic modelling literature to which these standards
apply is predominantly concerned with the cost-effective-
ness of treatment of diseases on health and outcomes (for
which the evidence is typically drawn from randomised
controlled trials), rather than the effect of risk factor
modification on health (for which the evidence may come
from trials but tends to be drawn from observational
studies). Moreover the health economic guidelines tend not
to be used when reporting NCD modelling, particularly in
the absence of an economic component to the modelling, as
they are perceived as inappropriate. Consequently, we
believe there is a need for specific non-communicable
disease reporting guidelines within our field.
Modelling has an important role in public health and
health policy. This may grow in the future, open access to
data and increased computing power are facilitating the
development of more sophisticated models. We recognise
there is a need to improve the reporting of our work in
terms of transparency and standardised reporting of both
models and model results. It is also important that we
continue to work in a collaborative fashion to develop the
science to support modelling and capacity within the UK to
undertake such work.
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